

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China NT Pharma Group Company Limited

中國泰凌醫藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 01011)

PROFIT WARNING

This announcement is made by the Company pursuant to Rule 13.09(1) of the Listing Rules.

The Board wishes to inform the shareholders of the Company and potential investors that based on a preliminary review of the Group's unaudited management accounts and the information currently available to the Board, the Board currently estimates that the Group could possibly record a loss for the six months ended 30 June 2012.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

This announcement is made by China NT Pharma Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company and potential investors that based on a preliminary review of the Group's unaudited management accounts and the information currently available to the Board, the Board currently estimates that the Group could possibly record a loss for the six months ended 30 June 2012. The loss is attributable to the Company's business restructuring measures introduced during the period in order to enhance its competitiveness and to improve cash flow, which involved gradual exiting from its vaccine and pharmaceutical supply chain business and downsizing of its vaccine sales and promotion team, and the resulting expenses incurred.

As the Group's interim results for the six months ended 30 June 2012 are not yet available, the information contained in this announcement represents only a preliminary assessment made by the Board based on the information made available to the Board as at the date hereof and such information or figure has not been audited nor reviewed by the Company's auditors.

The Board considers that the overall operational and financial positions of the Group remain solid and the Board remains positive on the long-term prospect of the Group.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
China NT Pharma Group Company Limited
Ng Tit
Chairman

Hong Kong, 27 July 2012

As at the date of this announcement, the executive director of the Company is Mr. Ng Tit; the non-executive directors of the Company are Ms. Chin Yu, Dr. Qian Wei and Mr. Stephen Cheuk Kin Law; and the independent non-executive directors of the Company are Mr. Yue Nien Martin Tang, Mr. Patrick Sun and Dr. Lap-Chee Tsui.